A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure

A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure

A first-in-human, phase 1, double blind, placebo-controlled, single ascending dose study examined the safety, tolerability, and exploratory efficacy of intravenous infusion of a recombinant growth factor, cimaglermin alfa, in patients with heart failure and left ventricular systolic dysfunction (LVS...

Full description

Bibliographic Details
Main Authors: Daniel J. Lenihan, MD, Sarah A. Anderson, ACNP, Carrie Geisberg Lenneman, MD, Evan Brittain, MD, MSCI, James A.S. Muldowney, III, MD, Lisa Mendes, MD, Ping Z. Zhao, PhD, Jennifer Iaci, MS, Stephen Frohwein, MD, Ronald Zolty, MD, PhD, Andrew Eisen, MD, PhD, Douglas B. Sawyer, MD, PhD, Anthony O. Caggiano, MD, PhD
Format: Article
Language:English
Published: Elsevier 2016-12-01
Series:JACC: Basic to Translational Science
Subjects:
cardiac repair
growth factor
neuregulin
systolic dysfunction
Online Access:http://www.sciencedirect.com/science/article/pii/S2452302X16301619

Internet

http://www.sciencedirect.com/science/article/pii/S2452302X16301619

Similar Items